Not a good buy right now for an impatient investor: price is stuck in a consolidation zone (below pivot 55.89) with weakening upside momentum and a bearish short-horizon pattern forecast.
Upside exists vs Street targets (mostly low/mid-$60s to $70s), but near-term commodity/oversupply uncertainty + upcoming earnings (2026-02-17 AH) make timing unfavorable for a “buy now” approach.
Volatility: 30D IV 41.63 vs historical vol 36.93 (options pricing in elevated risk). IV percentile 84.46 suggests IV is high versus the past year.
Activity: Today’s options volume (6,933) is well below 30D average (today vs avg ~33%), so sentiment read is less reliable due to light volume.
Takeaway: Options lean bullish, but IV is elevated (market bracing for a catalyst, likely earnings/commodity moves).
Technical Summary
Sell
1
Buy
14
Positive Catalysts
can be a catalyst if production/cash flow guidance surprises to the upside.
Neutral/Negative Catalysts
Near-term technical setup is not compelling: consolidation under pivot with fading MACD momentum; pattern-based forecast points to downside bias over the next month.
Earnings event risk on 2026-02-17 (AH): could trigger downside if cash flow/production/guidance misses expectations.
Analyst notes flag commodity uncertainty and longer-dated risks (e.g., oversupply risk into 2027 mentioned by BofA), which can cap multiple expansion.
News provided is not EQT-specific (largely about Novo Nordisk/Australian market items), offering no clear positive EQT catalyst from the headline set.
Financial Performance
Latest quarter provided: 2025/Q3
Revenue: $1.82B, up +49.78% YoY (strong top-line growth).
Profitability: Net income $335.9M, down -211.65% YoY; EPS $0.53, down -198.15% YoY (material earnings deterioration despite revenue growth).
Margins: Gross margin 36.15%, up +373.17% YoY (improved gross profitability, but it did not translate into higher bottom-line earnings in this period).
Ownership/trading behavior: Hedge funds neutral; insiders neutral (no strong conviction signal recently). No recent congress trading data; no notable politician/influential-figure transactions provided.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Rating trend: Overall still constructive (Buy/Overweight/Outperform common), but price targets were trimmed by several firms in Jan 2026 (Barclays, Stephens, Scotiabank, Citi; BofA cut notably from 84 to 74).
Recent target actions (sample):
Stephens: Overweight, PT 68 (down from 69)
Barclays: Overweight, PT 64 (down from 67)
Scotiabank: Sector Perform, PT 63 (down from 67)
Jefferies: Buy, PT 71 (up from 68)
BofA: Buy, PT 74 (down from 84)
Wall Street “pros”: low-cost/integrated asset base; expected resilience in upstream cash-return models; supportive longer-term natural gas fundamentals in some notes.
Wall Street “cons”: near-term commodity uncertainty; risk of future oversupply (notably 2027) prompting target cuts; Q4 cash flow/production expectations cited as slightly below consensus by at least one firm.
Wall Street analysts forecast EQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EQT is 65.18 USD with a low forecast of 50 USD and a high forecast of 76 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast EQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EQT is 65.18 USD with a low forecast of 50 USD and a high forecast of 76 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
6 Hold
0 Sell
Moderate Buy
Current: 55.330
Low
50
Averages
65.18
High
76
Current: 55.330
Low
50
Averages
65.18
High
76
Stephens
Mike Scialla
Overweight
downgrade
$69 -> $68
AI Analysis
2026-01-22
Reason
Stephens
Mike Scialla
Price Target
$69 -> $68
AI Analysis
2026-01-22
downgrade
Overweight
Reason
Stephens analyst Mike Scialla lowered the firm's price target on EQT Corporation to $68 from $69 and keeps an Overweight rating on the shares. The firm's Q4 cash flow per share and production estimates are 5% and 1% below consensus, respectively, notes the analyst, who looks for the stock to maintain its premium valuation to its natural gas peer group given the company's integrated assets and low-cost structure.
Barclays
Overweight
downgrade
$67 -> $64
2026-01-21
Reason
Barclays
Price Target
$67 -> $64
2026-01-21
downgrade
Overweight
Reason
Barclays lowered the firm's price target on EQT Corporation to $64 from $67 and keeps an Overweight rating on the shares. The firm adjusted ratings and targets in the exploration and production group as part of a Q4 preview. The upstream sector's cash return model "remains resilient" amid macro volatility, the analyst tells investors in a research note. Barclays see attractive opportunities in U.S. onshore. It tells investors to "tread carefully" through the near-term commodity uncertainty.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EQT
